AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...
GlobalData on MSN5d
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLCAstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback